amlodipine has been researched along with Obesity in 42 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
Excerpt | Relevance | Reference |
---|---|---|
"Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity." | 9.24 | Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017) |
"This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity." | 9.19 | Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014) |
"After a 4-week placebo period, 58 overweight-obese (BMI >or=25 kg/m(2)) patients, with mild to moderate essential hypertension (DBP >95 and <110 mmHg, SBP >140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study." | 9.13 | Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008) |
"The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 9.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
"To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 9.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
"We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51." | 7.71 | Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001) |
"To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients." | 7.68 | Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993) |
"Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes." | 6.75 | Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010) |
"Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently." | 6.49 | Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013) |
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 5.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
"Aliskiren penetrates adipose and skeletal muscle in hypertensive patients with abdominal obesity and reduces renin-angiotensin-aldosterone system activity." | 5.24 | Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension. ( Boschmann, M; Dahlke, M; Danser, AHJ; Dole, WP; Engeli, S; Jordan, J; May, M; Nussberger, J; Pal, P; Prescott, MF; Stitah, S, 2017) |
" We prospectively examined randomization to first-step chlorthalidone, a thiazide-type diuretic; amlodipine, a calcium-channel blocker; and lisinopril, an angiotensin-converting enzyme inhibitor, on BP control and cardiovascular outcomes in a hypertensive cohort stratified by baseline BMI [kg/m(2); normal weight (BMI <25), overweight (BMI = 25-29." | 5.19 | Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. ( Barzilay, JI; Dart, RA; Davis, BR; Einhorn, PT; Graves, JW; Pressel, SL; Reisin, E; Retta, TM; Saklayen, MG; Yamal, JM, 2014) |
"This prespecified subgroup analysis of a phase III study examined the effect of adding hydrochlorothiazide (HCTZ) to olmesartan (OLM)/amlodipine (AML) in patients with moderate to severe hypertension stratified by age, sex, body mass index, and hypertension severity." | 5.19 | Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. ( Ammentorp, B; de la Sierra, A; Kreutz, R; Laeis, P, 2014) |
"This was a prospective trial of amlodipine 10 mg/day administered for 1 month in primary-care patients with hypertension (n = 28), 46% of whom were obese and 57% of whom displayed the metabolic syndrome." | 5.15 | Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3. ( Bittar, R; Bonnefont-Rousselot, D; Bruckert, E; Chantepie, S; Chapman, MJ; Girerd, X; Hansel, B; Kontush, A; Orsoni, A, 2011) |
"After a 4-week placebo period, 58 overweight-obese (BMI >or=25 kg/m(2)) patients, with mild to moderate essential hypertension (DBP >95 and <110 mmHg, SBP >140 mmHg) were treated with amlodipine 5 mg od or valsartan 160 mg od or amlodipine 5 mg plus valsartan 160 mg od for 8 weeks according to a randomized, open-label, blinded end-point, cross-over study." | 5.13 | Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients. ( Corradi, L; Derosa, G; Fogari, R; Lazzari, P; Mugellini, A; Preti, P; Santoro, T; Zoppi, A, 2008) |
"The objective of this study was to assess the effect of amlodipine-atorvastatin combination on plasma interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha) and insulin sensitivity in normocholesterolemic obese hypertensive patients." | 5.12 | Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients. ( Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A, 2006) |
"To demonstrate that calcium channel blockers can improve insulin resistance clinically, we investigated the effects of the calcium channel blockers, amlodipine, manidipine and cilnidipine on serum levels of steroid hormones and insulin." | 5.11 | Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients. ( Miyachi, Y; Ueshiba, H, 2004) |
"The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition." | 5.11 | Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005) |
" This article considers the evidence supporting telmisartan/amlodipine combination therapy for the treatment of hypertension in patients with metabolic risk factors." | 4.89 | Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients). ( Ley, L; Schumacher, H, 2013) |
"The CD feeding induced obesity, hyperphagia, hyperlipidaemia, and leptin and insulin resistance." | 3.80 | Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. ( Barkhausen, J; Hübel, N; Mildner, M; Müller-Fielitz, H; Raasch, W; Vogt, FM, 2014) |
" Metformin treatment improved the insulin sensitivity, and normalized the in vitro bladder hypercontractility and cystometric dysfunction in obese mice." | 3.78 | Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice. ( Anhê, GF; Antunes, E; Calixto, MC; De Nucci, G; Grant, AD; Leiria, LO; Lintomen, L; Mónica, FZ; Sollon, C; Zanesco, A, 2012) |
"We investigated the effects of the calcium channel blocker amlodipine besilate on serum levels of adrenal androgens and insulin in 20 men with essential hypertension and obesity (age: 51." | 3.71 | Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity. ( Miyachi, Y; Tsuboi, K; Ueshiba, H, 2001) |
" Each of five groups of obese hypertensives were treated with the long-acting calcium channel blocker (CCB) amlodipine, the angiotensin converting enzyme (ACE) inhibitor enalapril with or without a weight reduction program, or a weight reduction program alone." | 3.71 | Weight reduction and pharmacologic treatment in obese hypertensives. ( Masuo, K; Mikami, H; Ogihara, T; Tuck, ML, 2001) |
"To evaluate the effects of long-term treatment antihypertensive with the dihydropyridine calcium antagonist amlodipine on insulin sensitivity, plasma insulin, and lipoprotein metabolism in obese hypertensive patients." | 3.68 | Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension. ( Böhlen, L; de Courten, M; Ferrari, P; Heynen, G; Riesen, W; Schneider, M; Shaw, S; Weidmann, P, 1993) |
"Hypertension and obesity are two major threats for public health." | 2.80 | The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin. ( Akkaya, N; Cakmak, M; Çelik, HT; Demircelik, B; Erdamar, H; Gok, S; Kazanci, F; Yigitoglu, R, 2015) |
"Hypertension is particularly prevalent in patients aged ≥65 years, those with a body mass index ≥30 kg m(-2), Blacks and those with type II diabetes." | 2.75 | Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. ( Chrysant, SG; Heyrman, R; Karki, S; Lee, J; Melino, M, 2010) |
"Amlodipine was used as the control drug." | 2.72 | Selective imidazoline agonist moxonidine in obese hypertensive patients. ( de Abreu, VG; Francischetti, EA; Sanjuliani, AF, 2006) |
"Amlodipine treatment 1) lowered fasting serum insulin (from 273 +/- 19 to 200 +/- 17 pmol/L; P < 0." | 2.67 | The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men. ( Beer, NA; Beer, RM; Jakubowicz, DJ; Nestler, JE, 1993) |
"Aliskiren is a novel renin-angiotensin aldosterone system (RAAS) inhibitor, the combination therapy of aliskiren and amlodipine for blood pressure control have been reported recently." | 2.49 | Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials. ( Chen, K; Han, Y; Kou, X; Liu, Y; Zeng, C; Zhou, L, 2013) |
"Treatment with amlodipine, candesartan, or indapamide did not significantly affect plasma visfatin levels." | 1.43 | Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations. ( Piecha, G; Skoczylas, A; Więcek, A, 2016) |
"Candesartan treatment may suppress all-cause death and reduce the incidence of new-onset diabetes in patients with obesity." | 1.36 | Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial. ( Fujimoto, A; Hirata, M; Nakao, K; Oba, K; Ogihara, T; Saruta, T; Ueshima, K; Yasuno, S, 2010) |
"Non-alcoholic steatohepatitis (NASH), which is a common liver disease in industrialized countries, is associated with obesity, hypertension, and type-2 diabetes (metabolic syndrome)." | 1.35 | ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats. ( Cao, G; Mastai, R; Mella, J; Muñoz, MC; Pereyra, L; Toblli, JE, 2008) |
"Heart failure was two times more prevalent in obese patients." | 1.34 | [Overweight and obesity in hypertensive Spanish patients. The CORONARIA study]. ( Aguilar Llopis, A; Arístegui Urrestarazu, R; Armada Peláez, B; Cosín Aguilar, J; Hernándiz Martínez, A; Masramón Morell, X; Rodríguez Padial, L; Zamorano Gómez, JL, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (7.14) | 18.2507 |
2000's | 15 (35.71) | 29.6817 |
2010's | 23 (54.76) | 24.3611 |
2020's | 1 (2.38) | 2.80 |
Authors | Studies |
---|---|
Chou, CL | 1 |
Li, CH | 1 |
Fang, TC | 1 |
Engeli, S | 4 |
May, M | 2 |
Nussberger, J | 2 |
Danser, AHJ | 1 |
Dole, WP | 1 |
Prescott, MF | 2 |
Dahlke, M | 2 |
Stitah, S | 1 |
Pal, P | 1 |
Boschmann, M | 2 |
Jordan, J | 4 |
Stinkens, R | 1 |
van der Kolk, BW | 1 |
Jax, T | 1 |
Heise, T | 1 |
Jocken, JW | 1 |
Schindler, C | 1 |
Havekes, B | 1 |
Schaper, N | 1 |
Albrecht, D | 1 |
Kaiser, S | 1 |
Hartmann, N | 1 |
Letzkus, M | 1 |
Langenickel, TH | 1 |
Goossens, GH | 1 |
Blaak, EE | 1 |
Roth, EM | 1 |
Oparil, S | 1 |
Melino, M | 2 |
Lee, J | 2 |
Fernandez, V | 1 |
Heyrman, R | 2 |
Liu, Y | 1 |
Chen, K | 1 |
Kou, X | 1 |
Han, Y | 1 |
Zhou, L | 1 |
Zeng, C | 1 |
Sweiss, N | 1 |
Sharma, K | 1 |
Müller-Fielitz, H | 1 |
Hübel, N | 1 |
Mildner, M | 1 |
Vogt, FM | 1 |
Barkhausen, J | 1 |
Raasch, W | 1 |
Reisin, E | 1 |
Graves, JW | 1 |
Yamal, JM | 1 |
Barzilay, JI | 1 |
Pressel, SL | 1 |
Einhorn, PT | 1 |
Dart, RA | 1 |
Retta, TM | 1 |
Saklayen, MG | 1 |
Davis, BR | 1 |
Kreutz, R | 1 |
Ammentorp, B | 1 |
Laeis, P | 1 |
de la Sierra, A | 1 |
Olszanecka-Glinianowicz, M | 1 |
Smertka, M | 1 |
Almgren-Rachtan, A | 1 |
Chudek, J | 1 |
Çelik, HT | 1 |
Akkaya, N | 1 |
Erdamar, H | 1 |
Gok, S | 1 |
Kazanci, F | 1 |
Demircelik, B | 1 |
Cakmak, M | 1 |
Yigitoglu, R | 1 |
Skoczylas, A | 1 |
Piecha, G | 1 |
Więcek, A | 1 |
Fogari, R | 2 |
Preti, P | 2 |
Zoppi, A | 2 |
Mugellini, A | 1 |
Corradi, L | 2 |
Lazzari, P | 2 |
Santoro, T | 1 |
Derosa, G | 2 |
Chrysant, SG | 1 |
Karki, S | 1 |
Nakao, K | 1 |
Hirata, M | 1 |
Oba, K | 1 |
Yasuno, S | 1 |
Ueshima, K | 1 |
Fujimoto, A | 1 |
Ogihara, T | 2 |
Saruta, T | 1 |
Sowers, JR | 2 |
Raij, L | 2 |
Jialal, I | 1 |
Egan, BM | 2 |
Ofili, EO | 1 |
Samuel, R | 2 |
Zappe, DH | 2 |
Purkayastha, D | 2 |
Deedwania, PC | 1 |
Punzi, H | 1 |
Shojaee, A | 2 |
Waverczak, WF | 1 |
Maa, JF | 2 |
Hansel, B | 1 |
Girerd, X | 1 |
Bonnefont-Rousselot, D | 1 |
Bittar, R | 1 |
Chantepie, S | 1 |
Orsoni, A | 1 |
Bruckert, E | 1 |
Chapman, MJ | 1 |
Kontush, A | 1 |
Danser, AH | 1 |
Yeh, CM | 1 |
Hsueh, WA | 1 |
Neutel, JM | 1 |
Leiria, LO | 1 |
Sollon, C | 1 |
Calixto, MC | 1 |
Lintomen, L | 1 |
Mónica, FZ | 1 |
Anhê, GF | 1 |
De Nucci, G | 1 |
Zanesco, A | 1 |
Grant, AD | 1 |
Antunes, E | 1 |
Ley, L | 1 |
Schumacher, H | 1 |
Weber, MA | 1 |
Jamerson, K | 1 |
Bakris, GL | 1 |
Weir, MR | 1 |
Zappe, D | 1 |
Zhang, Y | 1 |
Dahlof, B | 1 |
Velazquez, EJ | 1 |
Pitt, B | 1 |
Takagi, H | 1 |
Mizuno, Y | 1 |
Yamamoto, H | 1 |
Goto, SN | 1 |
Umemoto, T | 1 |
Ueshiba, H | 2 |
Miyachi, Y | 2 |
Ersoy, C | 1 |
Imamoğlu, S | 1 |
Budak, F | 1 |
Tuncel, E | 1 |
Ertürk, E | 1 |
Oral, B | 1 |
Ruilope, LM | 1 |
Malacco, E | 1 |
Khder, Y | 1 |
Kandra, A | 1 |
Bönner, G | 1 |
Heintz, D | 1 |
Sanjuliani, AF | 1 |
de Abreu, VG | 1 |
Francischetti, EA | 1 |
Fogari, E | 1 |
Ciccarelli, L | 1 |
Boye, SW | 1 |
Le Breton, S | 1 |
Keefe, DL | 1 |
Mori, Y | 1 |
Itoh, Y | 1 |
Tajima, N | 1 |
Cosín Aguilar, J | 1 |
Hernándiz Martínez, A | 1 |
Masramón Morell, X | 1 |
Arístegui Urrestarazu, R | 1 |
Aguilar Llopis, A | 1 |
Zamorano Gómez, JL | 1 |
Armada Peláez, B | 1 |
Rodríguez Padial, L | 1 |
Kagota, S | 1 |
Tada, Y | 1 |
Kubota, Y | 1 |
Nejime, N | 1 |
Yamaguchi, Y | 1 |
Nakamura, K | 1 |
Kunitomo, M | 1 |
Shinozuka, K | 1 |
Toblli, JE | 1 |
Muñoz, MC | 1 |
Cao, G | 1 |
Mella, J | 1 |
Pereyra, L | 1 |
Mastai, R | 1 |
Rosa, EC | 1 |
Zanella, MT | 1 |
Kohlmann, NE | 1 |
Ferreira, SR | 1 |
Plavnik, FL | 1 |
Ribeiro, AB | 1 |
Kohlmann, O | 1 |
Ruvolo, G | 1 |
Greco, E | 1 |
Speziale, G | 1 |
Di Natale, M | 1 |
Marino, B | 1 |
de Courten, M | 1 |
Ferrari, P | 1 |
Schneider, M | 1 |
Böhlen, L | 1 |
Shaw, S | 1 |
Riesen, W | 1 |
Heynen, G | 1 |
Weidmann, P | 1 |
Beer, NA | 1 |
Jakubowicz, DJ | 1 |
Beer, RM | 1 |
Nestler, JE | 1 |
Tsuboi, K | 1 |
Masuo, K | 1 |
Mikami, H | 1 |
Tuck, ML | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
[NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
A 16-week Double-blind, Randomized, Multicenter, Force-titration Study to Evaluate the Antihypertensive Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Therapy Compared to HCTZ Based Therapy in Obese, Hypertensive Patients[NCT00439738] | Phase 4 | 412 participants (Actual) | Interventional | 2006-12-31 | Completed | ||
A 10-week Multicenter,Forced-titration Study Using 24-hr ABPM to Evaluate the Efficacy of Valsartan/Hydrochlorothiazide (HCTZ) Treatment Regimen vs Conventional Treatment Regimen With Amlodipine and Hydrochlorothiazide (HCTZ) in Patients With Stage 2 Hype[NCT00425997] | Phase 4 | 480 participants (Anticipated) | Interventional | 2006-12-31 | Completed | ||
A Prospective, Open-Label, Titration Study to Evaluate the Efficacy and Safety Safety of AZOR in Multiple Subgroups of Hypertensive Subjects Who Are Non-Responders to Anti-Hypertensive Monotherapy[NCT00791258] | Phase 4 | 999 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
A Prospective, Multinational, Multicenter Trial to Compare the Effects of Amlodipine/Benazepril to Benazepril and Hydrochlorothiazide Combined on the Reduction of Cardiovascular Morbidity and Mortality in Patients With High Risk Hypertension[NCT00170950] | Phase 3 | 11,506 participants (Actual) | Interventional | 2003-10-31 | Terminated (stopped due to The study was terminated early because of significant efficacy results for the primary endpoint in favor of benazepril/amlodipine treatment.) | ||
A 12-week Randomized Double-blind Parallel Group Study to Evaluate the Efficacy and Safety of the Combination Aliskiren With HCTZ Compared to Irbesartan or Amlodipine With HCTZ or HCTZ Alone in Hypertensive Patients With BMI ≥ 30 kg/m2 Not Adequately Resp[NCT00219115] | Phase 3 | 493 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
Treatment of Essential Hypertension With Rasilez. Evaluation of Different Methods of Blood Pressure Measurements - Efficacy and Safety Evaluation[NCT01060865] | Phase 4 | 50 participants (Actual) | Interventional | 2010-03-31 | Terminated (stopped due to The participants signed an old version of the informed consent.) | ||
Molecular - Genetic Alterations in Adipose Tissue After Change in Therapy From ACE Inhibitors to AT1 Receptor Blockers in Patients With Essential Hypertension[NCT01444833] | 35 participants (Anticipated) | Interventional | 2008-10-31 | Recruiting | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
Intervention | mg/dL (Mean) | |||||
---|---|---|---|---|---|---|
Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
HCTZ +Amlodipine | 99.4 | 102.8 | 3.4 | 127.7 | 146.5 | 18.9 |
Valsartan/HCTZ (Hydrochlorothiazide) | 98.0 | 98.1 | -0.5 | 123.9 | 126.3 | 2.1 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
Intervention | mg/dL (Mean) | |||||
---|---|---|---|---|---|---|
Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minute) | |
HCTZ +Amlodipine | 20.37 | 23.62 | 3.67 | 95.95 | 120.01 | 28.07 |
Valsartan/HCTZ (Hydrochlorothiazide) | 19.66 | 23.45 | 3.41 | 92.04 | 116.04 | 24.68 |
After a 75 gram anhydrous glucose challenge 2 hours after an oral glucose tolerance test (NCT00439738)
Timeframe: Week 16
Intervention | mg/dL (Mean) | |||||
---|---|---|---|---|---|---|
Baseline visit (0 minutes) | Week 16 (0 minutes) | Change from baseline to week 16 (0 minutes) | Baseline visit (120 minutes) | Week 16 (120 minutes) | Change from baseline to week 16 (120 minutes) | |
HCTZ +Amlodipine | 0.47 | 0.47 | 0.00 | 0.10 | 0.10 | -0.01 |
Valsartan/HCTZ (Hydrochlorothiazide) | 0.45 | 0.46 | 0.01 | 0.11 | 0.10 | -0.01 |
(NCT00439738)
Timeframe: Baseline to Weeks 4, 8, 12 and 16
Intervention | mm Hg (Mean) | |||||
---|---|---|---|---|---|---|
Baseline | Week 4 | Week 8 | Week 12 | Week 16 | Change from baseline to week 16 | |
HCTZ +Amlodipine | 93.6 | 87.6 | 85.1 | 82.8 | 80.9 | -12.7 |
Valsartan/HCTZ (Hydrochlorothiazide) | 94.9 | 85.7 | 81.9 | 81.1 | 80.8 | -14.0 |
(NCT00439738)
Timeframe: Baseline to Week 8
Intervention | mm Hg (Mean) | ||
---|---|---|---|
Baseline | Week 8 | Change from baseline | |
HCTZ +Amlodipine | 159.0 | 137.5 | -21.5 |
Valsartan/HCTZ (Hydrochlorothiazide) | 159.7 | 131.2 | -28.6 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 140/90 mm Hg (NCT00439738)
Timeframe: Weeks 4, 8, 12 16 and End of Study (for patients that did not complete the last visit at week 16)
Intervention | participants (Number) | ||||
---|---|---|---|---|---|
Week 4 | Week 8 | Week 12 | Week 16 | End of study | |
HCTZ +Amlodipine | 69 | 102 | 112 | 140 | 146 |
Valsartan/HCTZ (Hydrochlorothiazide) | 91 | 123 | 122 | 124 | 133 |
Mean sitting systolic blood pressure/mean sitting diastolic blood pressure < 130/80 mm Hg (NCT00439738)
Timeframe: Week 4, 8, 12, 16, End of Study (for patients that did not complete the last visit at week 16)
Intervention | participants (Number) | ||||
---|---|---|---|---|---|
Week 4 | Week 8 | Week 12 | Week 16 | End of Study | |
HCTZ +Amlodipine | 18 | 23 | 46 | 65 | 68 |
Valsartan/HCTZ (Hydrochlorothiazide) | 33 | 59 | 57 | 62 | 68 |
(NCT00791258)
Timeframe: baseline to 12 weeks
Intervention | Percentage of participants (Number) |
---|---|
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 75.8 |
(NCT00791258)
Timeframe: baseline to 12 weeks
Intervention | Percentage of participants (Number) |
---|---|
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 84.3 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | mm Hg (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
24-hour mean systolic blood pressure | Mean daytime systolic blood pressure | Mean nighttime systolic blood pressure | Systolic blood pressure - last 2 hours of dose | Systolic blood pressure - last 4 hours of dose | Systolic blood pressure - last 6 hours of dose | 24-hour mean diastolic blood pressure | Mean daytime diastolic blood pressure | Mean nighttime diastolic blood pressure | Diastolic blood pressure - last 2 hours of dose | Diastolic blood pressure - last 4 hours of dose | Diastolic blood pressure - last 6 hours of dose | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -14.8 | -16.3 | -12.5 | -13.6 | -13.0 | -12.6 | -9.4 | -10.6 | -7.6 | -8.6 | -8.0 | -7.7 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8 a.m. to 4 p.m. Nighttime is defined as 10 p.m. to 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | mm Hg (Mean) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
24-hour mean systolic blood pressure | Mean daytime systolic blood pressure | Mean nighttime systolic blood pressure | Systolic blood pressure - last 2 hours of dose | Systolic blood pressure - last 4 hours of dose | Systolic blood pressure - last 6 hours of dose | 24-hour mean diastolic blood pressure | Mean daytime diastolic blood pressure | Mean nighttime diastolic blood pressure | Diastolic blood pressure - last 2 hours of dose | Diastolic blood pressure - last 4 hours of dose | Diastolic blood pressure - last 6 hours of dose | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -21.0 | -23.2 | -17.5 | -19.6 | -18.2 | -17.9 | -13.3 | -15.0 | -11.1 | -12.3 | -11.6 | -11.3 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | mm Hg (Mean) | ||||
---|---|---|---|---|---|
4 weeks, N=975 | 8 weeks, N=929 | 12 weeks, N=865 | 16 weeks, N=797 | 20 weeks, N=745 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -8.1 | -9.1 | -11.9 | -14.6 | -14.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | mm Hg (Mean) | ||||
---|---|---|---|---|---|
4 weeks, N=975 | 8 weeks, N=929 | 12 weeks, N=865 | 16 weeks, N=797 | 20 weeks, N=745 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | -14.6 | -16.6 | -21.8 | -26.0 | -26.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140/90 mm Hg, N=230 | 4 weeks: <135/80 mm Hg, N=230 | 4 weeks: <130/80 mm Hg, N=230 | 4 weeks: <120/80 mm Hg, N=230 | 8 weeks: <140/90 mm Hg, N=231 | 8 weeks: <135/80 mm Hg, N=231 | 8 weeks: <130/80 mm Hg, N=232 | 8 weeks: <120/80 mm Hg, N=232 | 12 weeks: <140/90mm Hg, N=232 | 12 weeks: <135/80 mm Hg, N=232 | 12 weeks: <130/80 mm Hg, N=232 | 12 weeks: <120/80 mm Hg, N=232 | 16 weeks: <140/90 mm Hg, N=232 | 16 weeks: <135/80 mm Hg, N=232 | 16 weeks: <130/80 mm Hg, N=232 | 16 weeks: <120/80 mm Hg, N=232 | 20 weeks: <140/90 mm Hg, N=232 | 20 weeks: <135/80 mm Hg, N=232 | 20 weeks: <130/80 mm Hg, N=232 | 20 weeks: <120/80 mm Hg, N=232 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 45.7 | 14.8 | 10.4 | 3.9 | 55.0 | 23.8 | 20.8 | 10.4 | 68.5 | 38.4 | 35.8 | 16.4 | 80.6 | 49.1 | 47.4 | 30.6 | 86.6 | 57.8 | 55.2 | 39.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=230 | 4 weeks: <85 mm Hg, N=230 | 4 weeks: <80 mm Hg, N=230 | 8 weeks: <90 mm Hg, N=231 | 8 weeks: <85 mm Hg, N=231 | 8 weeks: <80 mm Hg, N=231 | 12 weeks: <90 mm Hg, N=232 | 12 weeks: <85 mm Hg, N=232 | 12 weeks: <80 mm Hg, N=232 | 16 weeks: <90 mm Hg, N=232 | 16 weeks: <85 mm Hg, N=232 | 16 weeks: <80 mm Hg, N=232 | 20 weeks: <90 mm Hg, N=232 | 20 weeks: <85 mm Hg, N=232 | 20 weeks: <80 mm Hg, N=232 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 60.9 | 42.2 | 19.6 | 71.9 | 53.7 | 30.3 | 82.3 | 66.0 | 45.3 | 92.2 | 76.3 | 55.2 | 94.8 | 80.6 | 61.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=230 | 4 weeks: >10 and ≤ 15 mm Hg, N=230 | 4 weeks: >15 and ≤ 20 mm Hg, N=230 | 4 weeks: >20 mm Hg, N=230 | 8 weeks: ≤ 10 mm Hg, N=220 | 8 weeks: >10 and ≤ 15 mm Hg, N=220 | 8 weeks: >15 and ≤ 20 mm Hg, N=220 | 8 weeks: >20 mm Hg, N=220 | 12 weeks: ≤ 10 mm Hg, N=208 | 12 weeks: >10 and ≤15 mm Hg, N=208 | 12 weeks: >15 and ≤ 20 mm Hg, N=208 | 12 weeks: >20 mm Hg, N=208 | 16 weeks: ≤ 10 mm Hg, N=199 | 16 weeks: >10 and ≤ 15 mm Hg, N=199 | 16 weeks: >15 and ≤ 20 mm Hg, N=199 | 16 weeks: >20 mm Hg, N=199 | 20 weeks: ≤ 10 mm Hg, N=189 | 20 weeks: >10 and ≤ 15 mm Hg, N=189 | 20 weeks: >15 and ≤ 20 mm Hg, N=189 | 20 weeks: >20 mm Hg, N=189 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 70.0 | 17.8 | 7.9 | 4.4 | 66.8 | 15.0 | 10.9 | 7.3 | 54.8 | 21.2 | 12.0 | 12.0 | 38.7 | 19.6 | 23.1 | 18.6 | 36.0 | 19.6 | 20.6 | 23.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=230 | 4 weeks: <135 mm Hg, N=230 | 4 weeks: <130 mm Hg, N=230 | 4 weeks: <120 mm Hg, N=230 | 8 weeks: <140 mm Hg, N=231 | 8 weeks: <135 mm Hg, N=231 | 8 weeks: <130 mm Hg, N=231 | 8 weeks: <120 mm Hg, N=231 | 12 weeks: <140 mm Hg, N=232 | 12 weeks: <135 mm Hg, N=232 | 12 weeks: <130 mm Hg, N=232 | 12 weeks: <120 mm Hg, N=232 | 16 weeks: <140 mm Hg, N=232 | 16 weeks: <135 mm Hg, N=232 | 16 weeks: <130 mm Hg, N=232 | 16 weeks: <120 mm Hg, N=232 | 20 weeks: <140 mm Hg, N=232 | 20 weeks: <135 mm Hg, N=232 | 20 weeks: <130 mm Hg, N=232 | 20 weeks: <120 mm Hg, N=232 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.7 | 34.4 | 19.6 | 5.7 | 62.3 | 44.6 | 33.8 | 13.0 | 76.3 | 59.1 | 47.0 | 19.8 | 84.9 | 71.1 | 61.2 | 34.1 | 91.0 | 80.6 | 71.1 | 44.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=230 | 4 weeks: >15 and ≤ 30 mm Hg, N=230 | 4 weeks: >30 and ≤ 45 mm Hg, N=230 | 4 weeks: >45 mm Hg, N=230 | 8 weeks: ≤ 15 mm Hg, N=220 | 8 weeks: >15 and ≤ 30 mm Hg, N=220 | 8 weeks: >30 and ≤ 45 mm Hg, N=220 | 8 weeks: >45 mm Hg, N=220 | 12 weeks: ≤ 15 mm Hg, N=208 | 12 weeks: >15 and ≤ 30 mm Hg, N=208 | 12 weeks: >30 and ≤ 45 mm Hg, N=208 | 12 weeks: >45 mm Hg, N=208 | 16 weeks: ≤ 15 mm Hg, N=199 | 16 weeks: >15 and ≤ 30 mm Hg, N=199 | 16 weeks: >30 and ≤ 45 mm Hg, N=199 | 16 weeks: >45 mm Hg, N=199 | 20 weeks: ≤ 15 mm Hg, N=189 | 20 weeks: >15 and ≤ 30 mm Hg, N=189 | 20 weeks: >30 and ≤ 45 mm Hg, N=189 | 20 weeks: >45 mm Hg, N=189 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 60.0 | 32.2 | 7.4 | 0.4 | 53.6 | 38.2 | 7.3 | 0.9 | 38.9 | 41.8 | 16.4 | 2.9 | 30.7 | 37.2 | 25.1 | 7.0 | 24.3 | 37.6 | 29.6 | 8.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=128 | 4 weeks: <85 mm Hg, N=128 | 4 weeks: <80 mm Hg, N=128 | 8 weeks: <90 mm Hg, N=128 | 8 weeks: <85 mm Hg, N=128 | 8 weeks: <80 mm Hg, N=128 | 12 weeks: <90 mm Hg, N=128 | 12 weeks: <85 mm Hg, N=128 | 12 weeks: <80 mm Hg, N=128 | 16 weeks: <90 mm Hg, N=128 | 16 weeks: <85 mm Hg, N=128 | 16 weeks: <80 mm Hg, N=128 | 20 weeks: <90 mm Hg, N=128 | 20 weeks: <85 mm Hg, N=128 | 20 weeks: <80 mm Hg, N=128 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 83.6 | 69.5 | 45.3 | 89.1 | 79.7 | 60.2 | 95.3 | 87.5 | 71.1 | 96.9 | 93.0 | 82.0 | 96.9 | 93.0 | 85.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=126 | 4 weeks: >10 and ≤ 15 mm Hg, N=126 | 4 weeks: >15 and ≤ 20 mm Hg, N=126 | 4 weeks: >20 mm Hg, N=126 | 8 weeks: ≤ 10 mm Hg, N=123 | 8 weeks: >10 and ≤ 15 mm Hg, N=123 | 8 weeks: >15 and ≤ 20 mm Hg, N=123 | 8 weeks: >20 mm Hg, N=123 | 12 weeks: ≤ 10 mm Hg, N=120 | 12 weeks: >10 and ≤15 mm Hg, N=120 | 12 weeks: >15 and ≤ 20 mm Hg, N=120 | 12 weeks: >20 mm Hg, N=120 | 16 weeks: ≤ 10 mm Hg, N=112 | 16 weeks: >10 and ≤ 15 mm Hg, N=112 | 16 weeks: >15 and ≤ 20 mm Hg, N=112 | 16 weeks: >20 mm Hg, N=112 | 20 weeks: ≤ 10 mm Hg, N=105 | 20 weeks: >10 and ≤ 15 mm Hg, N=105 | 20 weeks: >15 and ≤ 20 mm Hg, N=105 | 20 weeks: >20 mm Hg, N=105 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 47.6 | 26.2 | 13.5 | 12.7 | 38.2 | 24.4 | 22.0 | 15.5 | 33.3 | 25.8 | 19.2 | 21.7 | 27.7 | 17.0 | 20.5 | 34.8 | 36.2 | 16.2 | 18.1 | 29.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=128 | 4 weeks: <135 mm Hg, N=128 | 4 weeks: <130 mm Hg, N=128 | 4 weeks: <120 mm Hg, N=128 | 8 weeks: <140 mm Hg, N=128 | 8 weeks: <135 mm Hg, N=128 | 8 weeks: <130 mm Hg, N=128 | 8 weeks: <120 mm Hg, N=128 | 12 weeks: <140 mm Hg, N=128 | 12 weeks: <135 mm Hg, N=128 | 12 weeks: <130 mm Hg, N=128 | 12 weeks: <120 mm Hg, N=128 | 16 weeks: <140 mm Hg, N=128 | 16 weeks: <135 mm Hg, N=128 | 16 weeks: <130 mm Hg, N=128 | 16 weeks: <120 mm Hg, N=128 | 20 weeks: <140 mm Hg, N=128 | 20 weeks: <135 mm Hg, N=128 | 20 weeks: <130 mm Hg, N=128 | 20 weeks: <120 mm Hg, N=128 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 64.8 | 51.6 | 35.2 | 11.7 | 76.6 | 67.2 | 51.6 | 25.0 | 89.1 | 78.9 | 66.4 | 38.3 | 95.3 | 89.8 | 81.3 | 47.7 | 97.7 | 93.0 | 85.9 | 51.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=126 | 4 weeks: >15 and ≤ 30 mm Hg, N=126 | 4 weeks: >30 and ≤ 45 mm Hg, N=126 | 4 weeks: >45 mm Hg, N=126 | 8 weeks: ≤ 15 mm Hg, N=123 | 8 weeks: >15 and ≤ 30 mm Hg, N=123 | 8 weeks: >30 and ≤ 45 mm Hg, N=123 | 8 weeks: >45 mm Hg, N=123 | 12 weeks: ≤ 15 mm Hg, N=120 | 12 weeks: >15 and ≤ 30 mm Hg, N=120 | 12 weeks: >30 and ≤ 45 mm Hg, N=120 | 12 weeks: >45 mm Hg, N=120 | 16 weeks: ≤ 15 mm Hg, N=112 | 16 weeks: >15 and ≤ 30 mm Hg, N=112 | 16 weeks: >30 and ≤ 45 mm Hg, N=112 | 16 weeks: >45 mm Hg, N=112 | 20 weeks: ≤ 15 mm Hg, N=105 | 20 weeks: >15 and ≤ 30 mm Hg, N=105 | 20 weeks: >30 and ≤ 45 mm Hg, N=105 | 20 weeks: >45 mm Hg, N=105 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 43.7 | 38.1 | 15.9 | 2.4 | 40.7 | 35.8 | 22.0 | 1.6 | 28.3 | 39.2 | 27.5 | 5.0 | 20.5 | 36.6 | 31.3 | 11.6 | 29.5 | 28.6 | 33.3 | 8.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=227 | 4 weeks: <85 mm Hg, N=227 | 4 weeks: <80 mm Hg, N=227 | 8 weeks: <90 mm Hg, N=227 | 8 weeks: <85 mm Hg, N=227 | 8 weeks: <80 mm Hg, N=227 | 12 weeks: <90 mm Hg, N=227 | 12 weeks: <85 mm Hg, N=227 | 12 weeks: <80 mm Hg, N=227 | 16 weeks: <90 mm Hg, N=227 | 16 weeks: <85 mm Hg, N=227 | 16 weeks: <80 mm Hg, N=227 | 20 weeks: <90 mm Hg, N=227 | 20 weeks: <85 mm Hg, N=227 | 20 weeks: <80 mm Hg, N=227 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.1 | 76.7 | 58.2 | 92.1 | 83.7 | 71.8 | 97.4 | 92.1 | 80.2 | 98.7 | 94.3 | 88.6 | 98.7 | 95.2 | 90.3 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=224 | 4 weeks: >10 and ≤ 15 mm Hg, N=224 | 4 weeks: >15 and ≤ 20 mm Hg, N=224 | 4 weeks: >20 mm Hg, N=224 | 8 weeks: ≤ 10 mm Hg, N=217 | 8 weeks: >10 and ≤ 15 mm Hg, N=217 | 8 weeks: >15 and ≤ 20 mm Hg, N=217 | 8 weeks: >20 mm Hg, N=217 | 12 weeks: ≤ 10 mm Hg, N=199 | 12 weeks: >10 and ≤15 mm Hg, N=199 | 12 weeks: >15 and ≤ 20 mm Hg, N=199 | 12 weeks: >20 mm Hg, N=199 | 16 weeks: ≤ 10 mm Hg, N=179 | 16 weeks: >10 and ≤ 15 mm Hg, N=179 | 16 weeks: >15 and ≤ 20 mm Hg, N=179 | 16 weeks: >20 mm Hg, N=179 | 20 weeks: ≤ 10 mm Hg, N=166 | 20 weeks: >10 and ≤ 15 mm Hg, N=166 | 20 weeks: >15 and ≤ 20 mm Hg, N=166 | 20 weeks: >20 mm Hg, N=166 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 63.8 | 20.5 | 9.4 | 6.3 | 57.1 | 19.8 | 14.3 | 8.8 | 45.2 | 25.1 | 15.6 | 14.1 | 27.4 | 25.1 | 22.9 | 24.6 | 34.9 | 20.5 | 24.1 | 20.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=227 | 4 weeks: <135 mm Hg, N=227 | 4 weeks: <130 mm Hg, N=227 | 4 weeks: <120 mm Hg, N=227 | 8 weeks: <140 mm Hg, N=227 | 8 weeks: <135 mm Hg, N=227 | 8 weeks: <130 mm Hg, N=227 | 8 weeks: <120 mm Hg, N=227 | 12 weeks: <140 mm Hg, N=227 | 12 weeks: <135 mm Hg, N=227 | 12 weeks: <130 mm Hg, N=227 | 12 weeks: <120 mm Hg, N=227 | 16 weeks: <140 mm Hg, N=227 | 16 weeks: <135 mm Hg, N=227 | 16 weeks: <130 mm Hg, N=227 | 16 weeks: <120 mm Hg, N=227 | 20 weeks: <140 mm Hg, N=227 | 20 weeks: <135 mm Hg, N=227 | 20 weeks: <130 mm Hg, N=227 | 20 weeks: <120 mm Hg, N=227 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 52.0 | 37.9 | 23.4 | 9.7 | 67.0 | 57.7 | 43.6 | 18.1 | 80.6 | 70.0 | 56.8 | 28.6 | 87.7 | 79.7 | 70.9 | 43.6 | 91.6 | 85.9 | 78.9 | 50.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=224 | 4 weeks: >15 and ≤ 30 mm Hg, N=224 | 4 weeks: >30 and ≤ 45 mm Hg, N=224 | 4 weeks: >45 mm Hg, N=224 | 8 weeks: ≤ 15 mm Hg, N=217 | 8 weeks: >15 and ≤ 30 mm Hg, N=217 | 8 weeks: >30 and ≤ 45 mm Hg, N=217 | 8 weeks: >45 mm Hg, N=217 | 12 weeks: ≤ 15 mm Hg, N=199 | 12 weeks: >15 and ≤ 30 mm Hg, N=199 | 12 weeks: >30 and ≤ 45 mm Hg, N=199 | 12 weeks: >45 mm Hg, N=199 | 16 weeks: ≤ 15 mm Hg, N=179 | 16 weeks: >15 and ≤ 30 mm Hg, N=179 | 16 weeks: >30 and ≤ 45 mm Hg, N=179 | 16 weeks: >45 mm Hg, N=179 | 20 weeks: ≤ 15 mm Hg, N=166 | 20 weeks: >15 and ≤ 30 mm Hg, N=166 | 20 weeks: >30 and ≤ 45 mm Hg, N=166 | 20 weeks: >45 mm Hg, N=166 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 47.3 | 40.2 | 11.2 | 1.3 | 42.9 | 37.8 | 16.6 | 2.8 | 26.6 | 46.7 | 24.6 | 2.0 | 17.9 | 32.4 | 39.7 | 10.1 | 14.5 | 37.4 | 38.0 | 10.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=98 | 4 weeks: <85 mm Hg, N=98 | 4 weeks: <80 mm Hg, N=98 | 8 weeks: <90 mm Hg, N=100 | 8 weeks: <85 mm Hg, N=100 | 8 weeks: <80 mm Hg, N=100 | 12 weeks: <90 mm Hg, N=100 | 12 weeks: <85 mm Hg, N=100 | 12 weeks: <80 mm Hg, N=100 | 16 weeks: <90 mm Hg, N=100 | 16 weeks: <85 mm Hg, N=100 | 16 weeks: <80 mm Hg, N=100 | 20 weeks: <90 mm Hg, N=100 | 20 weeks: <85 mm Hg, N=100 | 20 weeks: <80 mm Hg, N=100 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 66.3 | 53.1 | 34.7 | 85.0 | 70.0 | 48.0 | 92.0 | 78.0 | 62.0 | 96.0 | 90.0 | 75.0 | 96.0 | 90.0 | 75.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=98 | 4 weeks: >10 and ≤ 15 mm Hg, N=98 | 4 weeks: >15 and ≤ 20 mm Hg, N=98 | 4 weeks: >20 mm Hg, N=98 | 8 weeks: ≤ 10 mm Hg, N=91 | 8 weeks: >10 and ≤ 15 mm Hg, N=91 | 8 weeks: >15 and ≤ 20 mm Hg, N=91 | 8 weeks: >20 mm Hg, N=91 | 12 weeks: ≤ 10 mm Hg, N=83 | 12 weeks: >10 and ≤15 mm Hg, N=83 | 12 weeks: >15 and ≤ 20 mm Hg, N=83 | 12 weeks: >20 mm Hg, N=83 | 16 weeks: ≤ 10 mm Hg, N=75 | 16 weeks: >10 and ≤ 15 mm Hg, N=75 | 16 weeks: >15 and ≤ 20 mm Hg, N=75 | 16 weeks: >20 mm Hg, N=75 | 20 weeks: ≤ 10 mm Hg, N=71 | 20 weeks: >10 and ≤ 15 mm Hg, N=71 | 20 weeks: >15 and ≤ 20 mm Hg, N=71 | 20 weeks: >20 mm Hg, N=71 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 65.3 | 16.3 | 8.2 | 10.2 | 52.8 | 18.7 | 14.3 | 14.3 | 41.0 | 20.5 | 14.5 | 24.1 | 30.7 | 25.3 | 16.0 | 28.0 | 31.0 | 12.7 | 26.8 | 29.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=98 | 4 weeks: <135 mm Hg, N=98 | 4 weeks: <130 mm Hg, N=98 | 4 weeks: <120 mm Hg, N=98 | 8 weeks: <140 mm Hg, N=100 | 8 weeks: <135 mm Hg, N=100 | 8 weeks: <130 mm Hg, N=100 | 8 weeks: <120 mm Hg, N=100 | 12 weeks: <140 mm Hg, N=100 | 12 weeks: <135 mm Hg, N=100 | 12 weeks: <130 mm Hg, N=100 | 12 weeks: <120 mm Hg, N=100 | 16 weeks: <140 mm Hg, N=100 | 16 weeks: <135 mm Hg, N=100 | 16 weeks: <130 mm Hg, N=100 | 16 weeks: <120 mm Hg, N=100 | 20 weeks: <140 mm Hg, N=100 | 20 weeks: <135 mm Hg, N=100 | 20 weeks: <130 mm Hg, N=100 | 20 weeks: <120 mm Hg, N=100 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 55.1 | 39.8 | 31.6 | 10.2 | 64.0 | 51.0 | 41.0 | 15.0 | 77.0 | 67.0 | 54.0 | 30.0 | 84.0 | 77.0 | 66.0 | 37.0 | 88.0 | 83.0 | 72.0 | 41.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=98 | 4 weeks: >15 and ≤ 30 mm Hg, N=98 | 4 weeks: >30 and ≤ 45 mm Hg, N=98 | 4 weeks: >45 mm Hg, N=98 | 8 weeks: ≤ 15 mm Hg, N=91 | 8 weeks: >15 and ≤ 30 mm Hg, N=91 | 8 weeks: >30 and ≤ 45 mm Hg, N=91 | 8 weeks: >45 mm Hg, N=91 | 12 weeks: ≤ 15 mm Hg, N=83 | 12 weeks: >15 and ≤ 30 mm Hg, N=83 | 12 weeks: >30 and ≤ 45 mm Hg, N=83 | 12 weeks: >45 mm Hg, N=83 | 16 weeks: ≤ 15 mm Hg, N=75 | 16 weeks: >15 and ≤ 30 mm Hg, N=75 | 16 weeks: >30 and ≤ 45 mm Hg, N=75 | 16 weeks: >45 mm Hg, N=75 | 20 weeks: ≤ 15 mm Hg, N=71 | 20 weeks: >15 and ≤ 30 mm Hg, N=71 | 20 weeks: >30 and ≤ 45 mm Hg, N=71 | 20 weeks: >45 mm Hg, N=71 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 50.0 | 37.8 | 7.1 | 5.1 | 42.9 | 44.0 | 9.9 | 3.3 | 31.3 | 36.1 | 25.3 | 7.2 | 22.7 | 36.0 | 34.7 | 6.7 | 23.9 | 33.8 | 33.8 | 8.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=497 | 4 weeks: <85 mm Hg, N=497 | 4 weeks: <80 mm Hg, N=497 | 8 weeks: <90 mm Hg, N=497 | 8 weeks: <85 mm Hg, N=500 | 8 weeks: <80 mm Hg, N=500 | 12 weeks: <90 mm Hg, N=500 | 12 weeks: <85 mm Hg, N=500 | 12 weeks: <80 mm Hg, N=500 | 16 weeks: <90 mm Hg, N=500 | 16 weeks: <85 mm Hg, N=500 | 16 weeks: <80 mm Hg, N=500 | 20 weeks: <90 mm Hg, N=500 | 20 weeks: <85 mm Hg, N=500 | 20 weeks: <80 mm Hg, N=500 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 63.2 | 46.3 | 26.0 | 77.2 | 59.4 | 38.8 | 86.6 | 69.8 | 48.4 | 93.2 | 80.4 | 60.4 | 94.6 | 83.8 | 67.6 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=495 | 4 weeks: >10 and ≤ 15 mm Hg, N=495 | 4 weeks: >15 and ≤ 20 mm Hg, N=495 | 4 weeks: >20 mm Hg, N=495 | 8 weeks: ≤ 10 mm Hg, N=468 | 8 weeks: >10 and ≤ 15 mm Hg, N=468 | 8 weeks: >15 and ≤ 20 mm Hg, N=468 | 8 weeks: >20 mm Hg, N=468 | 12 weeks: ≤ 10 mm Hg, N=436 | 12 weeks: >10 and ≤15 mm Hg, N=436 | 12 weeks: >15 and ≤ 20 mm Hg, N=436 | 12 weeks: >20 mm Hg, N=436 | 16 weeks: ≤ 10 mm Hg, N=400 | 16 weeks: >10 and ≤ 15 mm Hg, N=400 | 16 weeks: >15 and ≤ 20 mm Hg, N=400 | 16 weeks: >20 mm Hg, N=400 | 20 weeks: ≤ 10 mm Hg, N=379 | 20 weeks: >10 and ≤ 15 mm Hg, N=379 | 20 weeks: >15 and ≤ 20 mm Hg, N=379 | 20 weeks: >20 mm Hg, N=379 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 67.5 | 17.8 | 8.5 | 6.3 | 59.4 | 19.9 | 13.0 | 7.7 | 48.9 | 22.5 | 16.1 | 12.6 | 33.3 | 23.0 | 19.0 | 24.8 | 31.9 | 18.7 | 22.4 | 26.9 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=497 | 4 weeks: <135 mm Hg, N=497 | 4 weeks: <130 mm Hg, N=497 | 4 weeks: <120 mm Hg, N=497 | 8 weeks: <140 mm Hg, N=500 | 8 weeks: <135 mm Hg, N=500 | 8 weeks: <130 mm Hg, N=500 | 8 weeks: <120 mm Hg, N=500 | 12 weeks: <140 mm Hg, N=500 | 12 weeks: <135 mm Hg, N=500 | 12 weeks: <130 mm Hg, N=500 | 12 weeks: <120 mm Hg, N=500 | 16 weeks: <140 mm Hg, N=500 | 16 weeks: <135 mm Hg, N=500 | 16 weeks: <130 mm Hg, N=500 | 16 weeks: <120 mm Hg, N=500 | 20 weeks: <140 mm Hg, N=500 | 20 weeks: <135 mm Hg, N=500 | 20 weeks: <130 mm Hg, N=500 | 20 weeks: <120 mm Hg, N=500 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.3 | 37.2 | 23.3 | 7.9 | 63.2 | 49.2 | 37.0 | 13.8 | 76.6 | 61.6 | 49.2 | 23.2 | 85.8 | 75.6 | 63.6 | 34.6 | 90.2 | 82.6 | 72.2 | 43.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=495 | 4 weeks: >15 and ≤ 30 mm Hg, N=495 | 4 weeks: >30 and ≤ 45 mm Hg, N=495 | 4 weeks: >45 mm Hg, N=495 | 8 weeks: ≤ 15 mm Hg, N=468 | 8 weeks: >15 and ≤ 30 mm Hg, N=468 | 8 weeks: >30 and ≤ 45 mm Hg, N=468 | 8 weeks: >45 mm Hg, N=468 | 12 weeks: ≤ 15 mm Hg, N=436 | 12 weeks: >15 and ≤ 30 mm Hg, N=436 | 12 weeks: >30 and ≤ 45 mm Hg, N=436 | 12 weeks: >45 mm Hg, N=436 | 16 weeks: ≤ 15 mm Hg, N=400 | 16 weeks: >15 and ≤ 30 mm Hg, N=400 | 16 weeks: >30 and ≤ 45 mm Hg, N=400 | 16 weeks: >45 mm Hg, N=400 | 20 weeks: ≤ 15 mm Hg, N=379 | 20 weeks: >15 and ≤ 30 mm Hg, N=379 | 20 weeks: >30 and ≤ 45 mm Hg, N=379 | 20 weeks: >45 mm Hg, N=379 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.0 | 35.2 | 8.5 | 0.4 | 52.4 | 35.9 | 10.3 | 1.5 | 37.8 | 42.4 | 17.4 | 2.5 | 27.8 | 36.0 | 27.5 | 8.8 | 20.6 | 37.5 | 33.3 | 8.7 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
24-hour mean systolic blood pressure <140 mmHg | 24-hour mean systolic blood pressure <135 mmHg | 24-hour mean systolic blood pressure <130 mmHg | 24-hour mean systolic blood pressure <120 mmHg | 24-hour mean diastolic blood pressure <90 mmHg | 24-hour mean diastolic blood pressure <85 mmHg | 24-hour mean diastolic blood pressure <80 mmHg | 24-hour mean blood pressure <140/90 mmHg | 24-hour mean blood pressure <135/95 mmHg | 24-hour mean blood pressure <135/80 mmHg | 24-hour mean blood pressure <130/80 mmHg | 24-hour mean blood pressure <125/75 mmHg | 24-hour mean blood pressure <120/80 mmHg | 24-hour mean blood pressure <120/70 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 95.6 | 90.4 | 79.9 | 47.2 | 98.7 | 96.1 | 84.7 | 94.3 | 89.1 | 80.3 | 73.4 | 52.4 | 45.9 | 27.5 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. (NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
24-hour mean systolic blood pressure <140 mmHg | 24-hour mean systolic blood pressure <135 mmHg | 24-hour mean systolic blood pressure <130 mmHg | 24-hour mean systolic blood pressure <120 mmHg | 24-hour mean diastolic blood pressure <90 mmHg | 24-hour mean diastolic blood pressure <85 mmHg | 24-hour mean diastolic blood pressure <80 mmHg | 24-hour mean blood pressure <140/90 mmHg | 24-hour mean blood pressure <135/95 mmHg | 24-hour mean blood pressure <135/80 mmHg | 24-hour mean blood pressure <130/80 mmHg | 24-hour mean blood pressure <125/75 mmHg | 24-hour mean blood pressure <120/80 mmHg | 24-hour mean blood pressure <120/70 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 99.5 | 97.5 | 94.5 | 70.4 | 100.0 | 97.5 | 93.0 | 99.5 | 96.0 | 92.5 | 90.5 | 75.4 | 70.4 | 55.3 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Daytime mean systolic blood pressure <140 mmHg | Daytime mean systolic blood pressure <135 mmHg | Daytime mean systolic blood pressure <130 mmHg | Daytime mean systolic blood pressure <120 mmHg | Daytime mean diastolic blood pressure <90 mmHg | Daytime mean diastolic blood pressure <85 mmHg | Daytime mean diastolic blood pressure <80 mmHg | Daytime mean blood pressure <140/90 mmHg | Daytime mean blood pressure <135/95 mmHg | Daytime mean blood pressure <135/80 mmHg | Daytime mean blood pressure <130/80 mmHg | Daytime mean blood pressure <125/75 mmHg | Daytime mean blood pressure <120/80 mmHg | Daytime mean blood pressure <120/70 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.2 | 79.9 | 66.4 | 28.8 | 95.6 | 83.0 | 65.5 | 86.9 | 72.9 | 61.1 | 53.3 | 31.9 | 27.9 | 13.1 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Daytime is defined as 8AM - 4PM. (NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Daytime mean systolic blood pressure <140 mmHg | Daytime mean systolic blood pressure <135 mmHg | Daytime mean systolic blood pressure <130 mmHg | Daytime mean systolic blood pressure <120 mmHg | Daytime mean diastolic blood pressure <90 mmHg | Daytime mean diastolic blood pressure <85 mmHg | Daytime mean diastolic blood pressure <80 mmHg | Daytime mean blood pressure <140/90 mmHg | Daytime mean blood pressure <135/95 mmHg | Daytime mean blood pressure <135/80 mmHg | Daytime mean blood pressure <130/80 mmHg | Daytime mean blood pressure <125/75 mmHg | Daytime mean blood pressure <120/80 mmHg | Daytime mean blood pressure <120/70 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 96.5 | 93.5 | 83.9 | 51.8 | 98.5 | 92.5 | 83.9 | 95.0 | 88.4 | 81.9 | 77.4 | 56.8 | 51.3 | 33.2 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nighttime mean systolic blood pressure <140 mmHg | Nighttime mean systolic blood pressure <135 mmHg | Nighttime mean systolic blood pressure <130 mmHg | Nighttime mean systolic blood pressure <120 mmHg | Nighttime mean diastolic blood pressure <90 mmHg | Nighttime mean diastolic blood pressure <85 mmHg | Nighttime mean diastolic blood pressure <80 mmHg | Nighttime mean blood pressure <140/90 mmHg | Nighttime mean blood pressure <135/95 mmHg | Nighttime mean blood pressure <135/80 mmHg | Nighttime mean blood pressure <130/80 mmHg | Nighttime mean blood pressure <125/75 mmHg | Nighttime mean blood pressure <120/80 mmHg | Nighttime mean blood pressure <120/70 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 97.8 | 94.3 | 92.6 | 74.7 | 99.6 | 98.3 | 94.8 | 97.4 | 93.4 | 90.8 | 89.1 | 77.7 | 74.2 | 62.0 |
Once the Ambulatory Blood Pressure Monitor (ABPM) has been applied, the dose of medication was taken and the subject wore the ABPM for a period of 24 hours. Nighttime is defined as 10 p.m. - 6 a.m. (NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | |||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Nighttime mean systolic blood pressure <140 mmHg | Nighttime mean systolic blood pressure <135 mmHg | Nighttime mean systolic blood pressure <130 mmHg | Nighttime mean systolic blood pressure <120 mmHg | Nighttime mean diastolic blood pressure <90 mmHg | Nighttime mean diastolic blood pressure <85 mmHg | Nighttime mean diastolic blood pressure <80 mmHg | Nighttime mean blood pressure <140/90 mmHg | Nighttime mean blood pressure <135/95 mmHg | Nighttime mean blood pressure <135/80 mmHg | Nighttime mean blood pressure <130/80 mmHg | Nighttime mean blood pressure <125/75 mmHg | Nighttime mean blood pressure <120/80 mmHg | Nighttime mean blood pressure <120/70 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 99.5 | 99.5 | 97.5 | 86.4 | 99.5 | 98.5 | 96.0 | 99.0 | 98.5 | 96.0 | 95.0 | 88.9 | 85.9 | 78.9 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 88.5 | 75.2 | 62.0 | 33.6 | 94.7 | 83.2 | 61.1 | 86.7 | 55.8 | 49.6 | 29.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 93.8 | 87.6 | 79.7 | 47.8 | 98.2 | 89.4 | 77.0 | 92.9 | 74.3 | 69.9 | 43.4 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 73.5 | 59.0 | 47.9 | 18.8 | 86.3 | 72.7 | 48.7 | 68.4 | 40.2 | 34.2 | 16.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 89.7 | 83.8 | 69.2 | 41.0 | 91.5 | 85.5 | 69.2 | 85.5 | 64.1 | 59.8 | 36.8 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.8 | 82.5 | 78.3 | 51.2 | 94.6 | 86.8 | 71.7 | 88.6 | 67.5 | 65.1 | 48.2 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.8 | 82.5 | 78.3 | 51.2 | 94.6 | 86.8 | 71.7 | 88.6 | 67.5 | 65.1 | 48.2 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 100.0 | 90.0 | 75.0 | 25.0 | 100.0 | 95.0 | 75.0 | 100.0 | 70.0 | 65.0 | 20.0 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 100.0 | 100.0 | 95.0 | 45.0 | 100.0 | 95.0 | 95.0 | 100.0 | 95.0 | 95.0 | 40.0 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 81.3 | 69.3 | 53.0 | 31.5 | 94.4 | 80.6 | 64.3 | 78.5 | 52.7 | 43.5 | 27.9 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 91.5 | 84.5 | 71.4 | 47.4 | 98.2 | 89.8 | 78.5 | 90.5 | 71.0 | 61.5 | 44.5 |
(NCT00791258)
Timeframe: Baseline to 12 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 80.8 | 69.2 | 56.0 | 26.1 | 89.7 | 76.9 | 59.0 | 76.1 | 52.6 | 46.2 | 23.1 |
(NCT00791258)
Timeframe: Baseline to 20 weeks
Intervention | Percentage of participants (Number) | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Systolic blood pressure <140 mmHg | Systolic blood pressure <135 mmHg | Systolic blood pressure <130 mmHg | Systolic blood pressure <120 mmHg | Diastolic blood pressure <90 mmHg | Diastolic blood pressure <85 mmHg | Diastolic blood pressure <80 mmHg | Blood pressure <140/90 mmHg | Blood pressure <135/80 mmHg | Blood pressure <130/80 mmHg | Blood pressure <120/80 mmHg | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 92.3 | 87.2 | 79.5 | 47.4 | 96.6 | 89.3 | 74.8 | 90.6 | 70.1 | 65.0 | 44.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140/90 mm Hg, N=975 | 4 weeks: <135/80 mm Hg, N=975 | 4 weeks: <130/80 mm Hg, N=975 | 4 weeks: <120/80 mm Hg, N=975 | 8 weeks: <140/90 mm Hg, N=929 | 8 weeks: <135/80 mm Hg, N=929 | 8 weeks: <130/80 mm Hg, N=929 | 8 weeks: <120/80 mm Hg, N=929 | 12 weeks: <140/90 mm Hg, N=865 | 12 weeks: <135/80 mm Hg, N=865 | 12 weeks: <130/80 mm Hg, N=865 | 12 weeks: <120/80 mm Hg, N=865 | 16 weeks: <140/90mm Hg, N=797 | 16 weeks: <135/80mm Hg, N=797 | 16 weeks: <130/80mm Hg, N=797 | 16 weeks: <120/80mm Hg, N=797 | 20 weeks: <140/90 mm Hg, N=745 | 20 weeks: <135/80 mm Hg, N=745 | 20 weeks: <130/80 mm Hg, N=745 | 20 weeks: <120/80 mm Hg, N=745 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 49.1 | 23.0 | 17.3 | 7.8 | 52.4 | 29.8 | 24.8 | 11.2 | 68.1 | 40.0 | 34.3 | 17.6 | 77.8 | 51.3 | 46.2 | 28.7 | 81.3 | 55.6 | 50.1 | 28.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=975 | 4weeks: <85 mm Hg, N=975 | 4 weeks: <80 mm Hg, N=975 | 8 weeks: <90 mm Hg, N=929 | 8 weeks: <85 mm Hg, N=929 | 8 weeks: <80 mm Hg, N=929 | 12 weeks: <90 mm Hg, N=865 | 12 weeks: <85 mm Hg, N=865 | 12 weeks: <80 mm Hg, N=865 | 16 weeks: <90 mm Hg, N=797 | 16 weeks: <85 mm Hg, N=797 | 16 weeks: <80 mm Hg, N=797 | 20 weeks: <90 mm Hg, N=745 | 20 weeks: <85 mm Hg, N=745 | 20 weeks: <80 mm Hg, N=745 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 71.3 | 55.2 | 34.2 | 75.1 | 57.1 | 40.2 | 84.3 | 68.7 | 49.5 | 90.2 | 76.9 | 59.6 | 89.7 | 79.5 | 62.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=975 | 4 weeks: >10 and ≤ 15 mm Hg, N=975 | 4 weeks: >15 and ≤ 20 mm Hg, N=975 | 4 weeks: >20 mm Hg, N=975 | 8 weeks: ≤ 10 mm Hg, N=929 | 8 weeks: >10 and ≤ 15 mm Hg, N=929 | 8 weeks: >15 and ≤ 20 mm Hg, N=929 | 8 weeks: >20 mm Hg, N=929 | 12 weeks: ≤ 10 mm Hg, N=865 | 12 weeks: >10 and ≤ 15 mm Hg, N=865 | 12 weeks: >15 and ≤ 20 mm Hg, N=865 | 12 weeks: >20 mm Hg, N=865 | 16 weeks: ≤ 10 mm Hg, N=797 | 16 weeks: >10 and ≤ 15 mm Hg, N=797 | 16 weeks: >15 and ≤ 20 mm Hg, N=797 | 16 weeks: >20 mm Hg, N=797 | 20 weeks: ≤ 10 mm Hg, N=745 | 20 weeks: >10 and ≤ 15 mm Hg, N=745 | 20 weeks: >15 and ≤ 20 mm Hg, N=745 | 20 weeks: >20 mm Hg, N=745 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 61.3 | 21.0 | 10.5 | 7.2 | 54.7 | 20.7 | 14.1 | 10.6 | 43.8 | 24.1 | 15.8 | 16.3 | 30.4 | 22.8 | 21.5 | 25.4 | 31.4 | 19.9 | 22.6 | 26.2 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=975 | 4 weeks: <135 mm Hg, N=975 | 4 weeks: <130 mm Hg, N=975 | 4 weeks: <120 mm Hg, N=975 | 8 weeks: <140 mm Hg, N=929 | 8 weeks: <135 mm Hg, N=929 | 8 weeks: <130 mm Hg, N=929 | 8 weeks: <120 mm Hg, N=929 | 12 weeks: <140 mm Hg, N=865 | 12 weeks: <135 mm Hg, N=865 | 12 weeks: <130 mm Hg, N=865 | 12 weeks: <120 mm Hg, N=865 | 16 weeks: <140 mm Hg, N=797 | 16 weeks: <135 mm Hg, N=797 | 16 weeks: <130 mm Hg, N=797 | 16 weeks: <120 mm Hg, N=797 | 20 weeks: <140 mm Hg, N=745 | 20 weeks: <135 mm Hg, N=745 | 20 weeks: <130 mm Hg, N=745 | 20 weeks: <120 mm Hg, N=745 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 54.2 | 39.8 | 25.3 | 8.9 | 57.2 | 45.9 | 35.0 | 12.9 | 72.6 | 59.0 | 45.3 | 19.4 | 80.9 | 70.3 | 58.9 | 30.9 | 84.3 | 75.2 | 64.2 | 31.5 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=975 | 4 weeks: >15 and ≤ 30 mm Hg, N=975 | 4 weeks: >30 and ≤ 45 mm Hg, N=975 | 4 weeks: >45 mm Hg, N=975 | 8 weeks: ≤ 15 mm Hg, N=929 | 8 weeks: >15 and ≤ 30 mm Hg, N=929 | 8 weeks: >30 and ≤ 45 mm Hg, N=929 | 8 weeks: >45 mm Hg, N=929 | 12 weeks: ≤ 15 mm Hg, N=865 | 12 weeks: >15 and ≤ 30 mm Hg, N=865 | 12 weeks: >30 and ≤ 45 mm Hg, N=865 | 12 weeks: >45 mm Hg, N=865 | 16 weeks: ≤ 15 mm Hg, N=797 | 16 weeks: >15 and ≤ 30 mm Hg, N=797 | 16 weeks: >30 and ≤ 45 mm Hg, N=797 | 16 weeks: >45 mm Hg, N=797 | 20 weeks: ≤ 15 mm Hg, N=745 | 20 weeks: >15 and ≤ 30 mm Hg, N=745 | 20 weeks: >30 and ≤ 45 mm Hg, N=745 | 20 weeks: >45 mm Hg, N=745 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 51.4 | 36.6 | 10.5 | 1.5 | 45.8 | 37.7 | 14.3 | 2.3 | 30.5 | 43.1 | 22.4 | 3.9 | 23.2 | 35.9 | 32.0 | 8.9 | 20.4 | 36.2 | 34.0 | 9.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=454 | 4 weeks: <85 mm Hg, N=454 | 4 weeks: <80 mm Hg, N=454 | 8 weeks: <90 mm Hg, N=457 | 8 weeks: <85 mm Hg, N=457 | 8 weeks: <80 mm Hg, N=457 | 12 weeks: <90 mm Hg, N=457 | 12 weeks: <85 mm Hg, N=457 | 12 weeks: <80 mm Hg, N=457 | 16 weeks: <90 mm Hg, N=457 | 16 weeks: <85 mm Hg, N=457 | 16 weeks: <80 mm Hg, N=457 | 20 weeks: <90 mm Hg, N=457 | 20 weeks: <85 mm Hg, N=457 | 20 weeks: <80 mm Hg, N=457 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 69.6 | 53.5 | 31.9 | 82.1 | 66.1 | 43.5 | 90.4 | 76.6 | 56.5 | 94.8 | 83.2 | 65.9 | 95.4 | 86.2 | 72.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=453 | 4 weeks: >10 and ≤ 15 mm Hg, N=453 | 4 weeks: >15 and ≤ 20 mm Hg, N=453 | 4 weeks: >20 mm Hg, N=453 | 8 weeks: ≤ 10 mm Hg, N=431 | 8 weeks: >10 and ≤ 15 mm Hg, N=431 | 8 weeks: >15 and ≤ 20 mm Hg, N=431 | 8 weeks: >20 mm Hg, N=431 | 12 weeks: ≤ 10 mm Hg, N=402 | 12 weeks: >10 and ≤15 mm Hg, N=402 | 12 weeks: >15 and ≤ 20 mm Hg, N=402 | 12 weeks: >20 mm Hg, N=402 | 16 weeks: ≤ 10 mm Hg, N=371 | 16 weeks: >10 and ≤ 15 mm Hg, N=371 | 16 weeks: >15 and ≤ 20 mm Hg, N=371 | 16 weeks: >20 mm Hg, N=371 | 20 weeks: ≤ 10 mm Hg, N=356 | 20 weeks: >10 and ≤ 15 mm Hg, N=356 | 20 weeks: >15 and ≤ 20 mm Hg, N=356 | 20 weeks: >20 mm Hg, N=356 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 62.7 | 22.3 | 8.6 | 6.4 | 56.6 | 19.7 | 15.3 | 8.4 | 44.3 | 22.1 | 17.4 | 16.2 | 32.4 | 24.0 | 21.0 | 22.6 | 33.2 | 19.4 | 22.5 | 25.0 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=454 | 4 weeks: <135 mm Hg, N=454 | 4 weeks: <130 mm Hg, N=454 | 4 weeks: <120 mm Hg, N=454 | 8 weeks: <140 mm Hg, N=457 | 8 weeks: <135 mm Hg, N=457 | 8 weeks: <130 mm Hg, N=457 | 8 weeks: <120 mm Hg, N=457 | 12 weeks: <140 mm Hg, N=457 | 12 weeks: <135 mm Hg, N=457 | 12 weeks: <130 mm Hg, N=457 | 12 weeks: <120 mm Hg, N=457 | 16 weeks: <140 mm Hg, N=457 | 16 weeks: <135 mm Hg, N=457 | 16 weeks: <130 mm Hg, N=457 | 16 weeks: <120 mm Hg, N=457 | 20 weeks: <140 mm Hg, N=457 | 20 weeks: <135 mm Hg, N=457 | 20 weeks: <130 mm Hg, N=457 | 20 weeks: <120 mm Hg, N=457 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.4 | 41.4 | 27.1 | 7.9 | 67.6 | 54.3 | 40.9 | 16.2 | 81.4 | 67.2 | 54.1 | 27.6 | 88.8 | 80.3 | 67.0 | 39.0 | 91.5 | 85.6 | 74.8 | 47.1 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=453 | 4 weeks: >15 and ≤ 30 mm Hg, N=453 | 4 weeks: >30 and ≤ 45 mm Hg, N=453 | 4 weeks: >45 mm Hg, N=453 | 8 weeks: ≤ 15 mm Hg, N=431 | 8 weeks: >15 and ≤ 30 mm Hg, N=431 | 8 weeks: >30 and ≤ 45 mm Hg, N=431 | 8 weeks: >45 mm Hg, N=431 | 12 weeks: ≤ 15 mm Hg, N=402 | 12 weeks: >15 and ≤ 30 mm Hg, N=402 | 12 weeks: >30 and ≤ 45 mm Hg, N=402 | 12 weeks: >45 mm Hg, N=402 | 16 weeks: ≤ 15 mm Hg, N=371 | 16 weeks: >15 and ≤ 30 mm Hg, N=371 | 16 weeks: >30 and ≤ 45 mm Hg, N=371 | 16 weeks: >45 mm Hg, N=371 | 20 weeks: ≤ 15 mm Hg, N=356 | 20 weeks: >15 and ≤ 30 mm Hg, N=356 | 20 weeks: >30 and ≤ 45 mm Hg, N=356 | 20 weeks: >45 mm Hg, N=356 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 49.5 | 38.4 | 11.5 | 0.7 | 48.0 | 35.5 | 14.4 | 2.1 | 30.4 | 43.8 | 22.6 | 3.2 | 24.0 | 37.7 | 29.1 | 9.2 | 19.7 | 36.5 | 36.0 | 7.9 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <90 mm Hg, N=190 | 4 weeks: <85 mm Hg, N=190 | 4 weeks: <80 mm Hg, N=190 | 8 weeks: <90 mm Hg, N=190 | 8 weeks: <85 mm Hg, N=190 | 8 weeks: <80 mm Hg, N=190 | 12 weeks: <90 mm Hg, N=190 | 12 weeks: <85 mm Hg, N=190 | 12 weeks: <80 mm Hg, N=190 | 16 weeks: <90 mm Hg, N=190 | 16 weeks: <85 mm Hg, N=190 | 16 weeks: <80 mm Hg, N=190 | 20 weeks: <90 mm Hg, N=190 | 20 weeks: <85 mm Hg, N=190 | 20 weeks: <80 mm Hg, N=190 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 75.8 | 64.2 | 39.0 | 85.8 | 72.6 | 51.1 | 94.2 | 83.2 | 63.7 | 97.9 | 89.0 | 70.5 | 99.0 | 90.5 | 76.8 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 10 mm Hg, N=189 | 4 weeks: >10 and ≤ 15 mm Hg, N=189 | 4 weeks: >15 and ≤ 20 mm Hg, N=189 | 4 weeks: >20 mm Hg, N=189 | 8 weeks: ≤ 10 mm Hg, N=181 | 8 weeks: >10 and ≤ 15 mm Hg, N=181 | 8 weeks: >15 and ≤ 20 mm Hg, N=181 | 8 weeks: >20 mm Hg, N=181 | 12 weeks: ≤ 10 mm Hg, N=170 | 12 weeks: >10 and ≤15 mm Hg, N=170 | 12 weeks: >15 and ≤ 20 mm Hg, N=170 | 12 weeks: >20 mm Hg, N=170 | 16 weeks: ≤ 10 mm Hg, N=156 | 16 weeks: >10 and ≤ 15 mm Hg, N=156 | 16 weeks: >15 and ≤ 20 mm Hg, N=156 | 16 weeks: >20 mm Hg, N=156 | 20 weeks: ≤ 10 mm Hg, N=150 | 20 weeks: >10 and ≤ 15 mm Hg, N=150 | 20 weeks: >15 and ≤ 20 mm Hg, N=150 | 20 weeks: >20 mm Hg, N=150 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 67.7 | 16.9 | 11.6 | 3.7 | 60.8 | 20.4 | 14.9 | 3.9 | 41.2 | 32.4 | 12.9 | 13.5 | 32.7 | 26.9 | 21.8 | 18.6 | 37.3 | 18.0 | 26.0 | 18.7 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: <140 mm Hg, N=190 | 4 weeks: <135 mm Hg, N=190 | 4 weeks: <130 mm Hg, N=190 | 4 weeks: <120 mm Hg, N=190 | 8 weeks: <140 mm Hg, N=190 | 8 weeks: <135 mm Hg, N=190 | 8 weeks: <130 mm Hg, N=190 | 8 weeks: <120 mm Hg, N=190 | 12 weeks: <140 mm Hg, N=190 | 12 weeks: <135 mm Hg, N=190 | 12 weeks: <130 mm Hg, N=190 | 12 weeks: <120 mm Hg, N=190 | 16 weeks: <140 mm Hg, N=190 | 16 weeks: <135 mm Hg, N=190 | 16 weeks: <130 mm Hg, N=190 | 16 weeks: <120 mm Hg, N=190 | 20 weeks: <140 mm Hg, N=190 | 20 weeks: <135 mm Hg, N=190 | 20 weeks: <130 mm Hg, N=190 | 20 weeks: <120 mm Hg, N=190 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 54.7 | 41.1 | 26.3 | 10.0 | 69.0 | 56.3 | 42.6 | 15.8 | 81.6 | 69.5 | 57.9 | 30.0 | 87.9 | 79.0 | 69.0 | 39.5 | 91.1 | 84.2 | 75.3 | 48.4 |
(NCT00791258)
Timeframe: Baseline to 4, 8, 12, 16, 20 weeks
Intervention | Percentage of Participants (Number) | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
4 weeks: ≤ 15 mm Hg, N=189 | 4 weeks: >15 and ≤ 30 mm Hg, N=189 | 4 weeks: >30 and ≤ 45 mm Hg, N=189 | 4 weeks: >45 mm Hg, N=189 | 8 weeks: ≤ 15 mm Hg, N=181 | 8 weeks: >15 and ≤ 30 mm Hg, N=181 | 8 weeks: >30 and ≤ 45 mm Hg, N=181 | 8 weeks: >45 mm Hg, N=181 | 12 weeks: ≤ 15 mm Hg, N=170 | 12 weeks: >15 and ≤ 30 mm Hg, N=170 | 12 weeks: >30 and ≤ 45 mm Hg, N=170 | 12 weeks: >45 mm Hg, N=170 | 16 weeks: ≤ 15 mm Hg, N=156 | 16 weeks: >15 and ≤ 30 mm Hg, N=156 | 16 weeks: >30 and ≤ 45 mm Hg, N=156 | 16 weeks: >45 mm Hg, N=156 | 20 weeks: ≤ 15 mm Hg, N=150 | 20 weeks: >15 and ≤ 30 mm Hg, N=150 | 20 weeks: >30 and ≤ 45 mm Hg, N=150 | 20 weeks: >45 mm Hg, N=150 | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 56.1 | 36.0 | 7.9 | 0.0 | 54.1 | 34.3 | 11.6 | 0.0 | 35.3 | 38.2 | 22.9 | 3.5 | 28.2 | 40.4 | 26.3 | 5.1 | 26.0 | 40.0 | 26.7 | 7.3 |
(NCT00791258)
Timeframe: Baseline to 12 and 20 weeks
Intervention | Percentage of participants (Number) | |
---|---|---|
12 weeks | 20 weeks | |
Olmesartan Medoxomil/Amlodipine Tablets + Hydrochlorothiazide | 71.3 | 84.8 |
CV mortality was defined as death due to sudden cardiac death, fatal MI, fatal stroke, coronary intervention, congestive heart failure (CHF), or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV mortality event, MI (non-fatal), or stroke (non-fatal) (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
Intervention | Percentage of Patients with an Event (Number) |
---|---|
Benazepril/Amlodipine | 5.0 |
Benazepril/Hydrochlorothiazide | 6.3 |
Cardiovascular morbidity was defined as including any of the following events: non-fatal MI, non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure (PCI or CABG). (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])]
Intervention | Percentage of Patients with an Event (Number) |
---|---|
Benazepril/Amlodipine | 8.6 |
Benazepril/Hydrochlorothiazide | 10.3 |
CV morbidity was defined as non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable angina, resuscitated sudden death, or coronary revascularization procedure. CV mortality was defined as death due to MI, stroke, coronary intervention, congestive heart failure (CHF), sudden cardiac death, or other CV causes. (NCT00170950)
Timeframe: For each patient, baseline to time of first CV morbidity or mortality event (or last exposure if no event occurred). (Median duration of exposure was 33.4 months. [25th to 75th percentiles: 21 to 41 months.])
Intervention | Percentage of Patients with an event (Number) |
---|---|
Benazepril/Amlodipine | 9.6 |
Benazepril/Hydrochlorothiazide | 11.8 |
4 reviews available for amlodipine and Obesity
Article | Year |
---|---|
Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.
Topics: Amides; Amlodipine; Antihypertensive Agents; Blood Pressure; Fumarates; Humans; Hypertension; Obesit | 2013 |
Adiponectin effects on the kidney.
Topics: Adiponectin; Albuminuria; Amlodipine; AMP-Activated Protein Kinases; Animals; Benzimidazoles; Benzoa | 2014 |
Telmisartan plus amlodipine single-pill combination for the management of hypertensive patients with a metabolic risk profile (added-risk patients).
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzimidazoles; Benzo | 2013 |
Effects of telmisartan therapy on interleukin-6 and tumor necrosis factor-alpha levels: a meta-analysis of randomized controlled trials.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Calc | 2013 |
21 trials available for amlodipine and Obesity
Article | Year |
---|---|
Systemic and tissue-specific effects of aliskiren on the RAAS and carbohydrate/lipid metabolism in obese patients with hypertension.
Topics: Adipose Tissue; Adult; Amides; Amlodipine; Angiotensin II; Antihypertensive Agents; Blood Glucose; D | 2017 |
The effects of angiotensin receptor neprilysin inhibition by sacubitril/valsartan on adipose tissue transcriptome and protein expression in obese hypertensive patients.
Topics: Adipose Tissue; Adult; Aminobutyrates; Amlodipine; Angiotensin Receptor Antagonists; Biphenyl Compou | 2018 |
Olmesartan/amlodipine/hydrochlorothiazide in obese participants with hypertension: a TRINITY subanalysis.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Body Mass Index; Double-Blind Meth | 2013 |
Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT.
Topics: Aged; Aged, 80 and over; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agen | 2014 |
Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: a subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity.
Topics: Adult; Age Factors; Aged; Amlodipine; Blood Pressure; Body Mass Index; Dose-Response Relationship, D | 2014 |
The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin.
Topics: Adult; Amlodipine; Antihypertensive Agents; Blood Proteins; Calcium; Carrier Proteins; Female; Fibro | 2015 |
Effect of valsartan addition to amlodipine on insulin sensitivity in overweight-obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Cross-Over Studies; Drug Therapy, Combination; Female; Humans; Hypertension | 2008 |
Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension.
Topics: Age Factors; Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Bla | 2010 |
Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Blood Glucose; Blood Pressure; Body Mass | 2010 |
Blood pressure-lowering response to amlodipine as a determinant of the antioxidative activity of small, dense HDL3.
Topics: Aged; Amlodipine; Antihypertensive Agents; Antioxidants; Blood Pressure; Body Mass Index; Calcium Ch | 2011 |
Office and ambulatory blood pressure-lowering effects of combination valsartan/hydrochlorothiazide vs. hydrochlorothiazide-based therapy in obese, hypertensive patients.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Co | 2011 |
Aliskiren penetrates adipose and skeletal muscle tissue and reduces renin-angiotensin system activity in obese hypertensive patients.
Topics: Adipose Tissue; Adult; Amides; Amlodipine; Antihypertensive Agents; Calcium Channel Blockers; Extrac | 2012 |
Efficacy of amlodipine/olmesartan medoxomil ± HCTZ in obese patients uncontrolled on antihypertensive monotherapy.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Drug Therapy, Combination; Female; Humans; Hydroch | 2012 |
Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the ACCOMPLISH randomised controlled trial.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Body Mass Index; Body Size; Body Weight; Ca | 2013 |
Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients.
Topics: Aged; Amlodipine; Analysis of Variance; Body Mass Index; Calcium Channel Blockers; Dehydroepiandrost | 2004 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D | 2005 |
Selective imidazoline agonist moxonidine in obese hypertensive patients.
Topics: Adult; Amlodipine; Anthropometry; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertensio | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel B | 2006 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Direct Renin inhibition with aliskiren in obese patients with arterial hypertension.
Topics: Administration, Oral; Adult; Aged; Amides; Amlodipine; Antihypertensive Agents; Biphenyl Compounds; | 2007 |
Blood pressure and cardiorenal responses to antihypertensive therapy in obese women.
Topics: Adult; Amlodipine; Analysis of Variance; Antihypertensive Agents; Blood Pressure; Blood Pressure Mon | 2008 |
The calcium channel blocker amlodipine raises serum dehydroepiandrosterone sulfate and androstenedione, but lowers serum cortisol, in insulin-resistant obese and hypertensive men.
Topics: Adult; Amlodipine; Androgens; Androstenedione; Calcium Channel Blockers; Dehydroepiandrosterone; Deh | 1993 |
17 other studies available for amlodipine and Obesity
Article | Year |
---|---|
Benefits of Valsartan and Amlodipine in Lipolysis through PU.1 Inhibition in Fructose-Induced Adiposity.
Topics: Activating Transcription Factor 3; Adiposity; Amlodipine; Angiotensin Receptor Antagonists; Antihype | 2022 |
Chronic blockade of angiotensin AT₁ receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Anti-Obesity Agents; Antihypertensive | 2014 |
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status.
Topics: Amlodipine; Antihypertensive Agents; Blood Pressure; Drug Combinations; Humans; Hypertension; Medica | 2014 |
Effects of antihypertensive treatment on plasma apelin, resistin, and visfatin concentrations.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers; | 2016 |
Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Topics: Aged; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Benzimidazoles; | 2010 |
Efficacy of amlodipine and olmesartan medoxomil in hypertensive patients with diabetes and obesity.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Antihypertensiv | 2011 |
Role of PKC and CaV1.2 in detrusor overactivity in a model of obesity associated with insulin resistance in mice.
Topics: Adiposity; Amlodipine; Animals; Body Weight; Calcium Channel Blockers; Calcium Channels, L-Type; Cal | 2012 |
Effect of amlodipine on insulin resistance & tumor necrosis factor-alpha levels in hypertensive obese type 2 diabetic patients.
Topics: Adolescent; Adult; Aged; Amlodipine; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Female; Ho | 2004 |
Adult hypertension: reducing cardiovascular morbidity and mortality.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Alcohol Drinking | 2005 |
Angiotensin II receptor blockers downsize adipocytes in spontaneously type 2 diabetic rats with visceral fat obesity.
Topics: Adipocytes; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; | 2007 |
[Overweight and obesity in hypertensive Spanish patients. The CORONARIA study].
Topics: Amlodipine; Analysis of Variance; Antihypertensive Agents; Body Mass Index; Calcium Channel Blockers | 2007 |
Peroxynitrite is Involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats.
Topics: Acetylcholine; Amlodipine; Animals; Aorta, Thoracic; Blood Glucose; Blood Pressure; Blotting, Wester | 2007 |
ACE inhibition and AT1 receptor blockade prevent fatty liver and fibrosis in obese Zucker rats.
Topics: Amlodipine; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme I | 2008 |
[The effect on left ventricular mass of treatment with amlodipine and diet therapy in obese patients with arterial hypertension].
Topics: Amlodipine; Combined Modality Therapy; Diet, Reducing; Evaluation Studies as Topic; Female; Heart Ve | 1994 |
Lack of effect of long-term amlodipine on insulin sensitivity and plasma insulin in obese patients with essential hypertension.
Topics: Amlodipine; Blood Pressure; Female; Humans; Hypertension; Insulin; Insulin Resistance; Male; Middle | 1993 |
Effects of amlodipine on serum levels of adrenal androgens and insulin in hypertensive men with obesity.
Topics: Adult; Aged; Amlodipine; Calcium Channel Blockers; Dehydroepiandrosterone; Dehydroepiandrosterone Su | 2001 |
Weight reduction and pharmacologic treatment in obese hypertensives.
Topics: Adult; Amlodipine; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; C | 2001 |